Alembic Pharmaceuticals appoints Sujit Bhayani as independent director

Alembic Pharmaceuticals has appointed Sujit Jaysukh Bhayani as a Non-Executive Independent Director, effective June 18, 2026, for a period of five years. The appointment was approved by the Board of Directors through a circular resolution based on the recommendation of the Nomination and Remuneration Committee. This decision strengthens the company's governance structure with the addition of an experienced industry professional.

The appointment is subject to the approval of shareholders at the ensuing Annual General Meeting. Upon approval, Bhayani will not be liable to retire by rotation. The company confirmed that the new appointee is not debarred from holding the office of Director by any SEBI order or other authority.

Profile of the Appointee

Sujit Jaysukh Bhayani is the Founder and Managing Director of the Sudeep Group. He holds a Bachelor's degree in Chemistry from the University of Tulsa and possesses more than 35 years of experience in the pharmaceuticals industry. Previously, he served as a Director of Dinesh Remedies Limited.

Key Details of Appointment

Particulars	Details
Name	Mr. Sujit Jaysukh Bhayani
DIN	01767427
Designation	Non-Executive Independent Director
Date of Appointment	June 18, 2026
Term	5 years
Shareholder Approval	Required at ensuing AGM

The company has disclosed that Bhayani is not related to any of the Directors or Key Managerial Personnel of Alembic Pharmaceuticals.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.48%	+1.70%	-4.39%	-11.50%	-22.65%	-24.28%

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for Tretinoin Cream USP, 0.05%, expanding its dermatology portfolio in the US generics market. The approval covers the Abbreviated New Drug Application (ANDA) for the product, which is therapeutically equivalent to the reference listed drug Retin-A Cream, 0.05%, marketed by Bausch Health US, LLC. The estimated market size for Tretinoin Cream USP, 0.05% is $76 million for the twelve months ending March 2026, according to IQVIA data.

Regulatory and Product Details

The USFDA final approval allows Alembic to market Tretinoin Cream USP, 0.05% for topical application in the treatment of acne vulgaris. The approval strengthens the company's presence in the US market, which is a key geography for its generic business.

Parameter	Details
Approved Product	Tretinoin Cream USP, 0.05%
Reference Listed Drug	Retin-A Cream, 0.05%
RLD Marketer	Bausch Health US, LLC
Approval Type	Final Approval (ANDA)
Therapeutic Indication	Acne vulgaris
Estimated Market Size	$76 million
Market Data Period	Twelve months ending March 2026

Strategic Context

With this approval, Alembic Pharmaceuticals now holds a cumulative total of 242 ANDA approvals from the USFDA, comprising 222 final approvals and 20 tentative approvals. This milestone underscores the company's consistent execution in its US generics pipeline and its capability to complex product development.